Supplementary Figure S6 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 6. Tumor biopsy gene expression changes in antigen presenting pathways after SYNB1891 treatment.
Language: English
Topic: Bacterial Cancer Therapy
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4383224814
Cites:
Cited by:
Related to: